RDY - Dr. Reddy's Laboratories Limited

NYSE - NYSE Delayed Price. Currency in USD
51.89
-0.37 (-0.71%)
At close: 4:00PM EDT

51.89 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close52.26
Open52.00
Bid51.93 x 800
Ask51.97 x 800
Day's Range51.42 - 52.41
52 Week Range33.33 - 55.19
Volume225,088
Avg. Volume217,811
Market Cap8.577B
Beta (5Y Monthly)-0.04
PE Ratio (TTM)36.96
EPS (TTM)1.40
Earnings DateN/A
Forward Dividend & Yield0.33 (0.63%)
Ex-Dividend DateJul 10, 2020
1y Target Est42.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
31% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    India's Cipla set to undercut rivals with generic remdesivir -sources

    Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.

  • Mylan to launch generic remdesivir version in India at $64 per 100 mg vial
    Reuters

    Mylan to launch generic remdesivir version in India at $64 per 100 mg vial

    Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country. The Drug Controller General of India (DCGI) approved Mylan's remdesivir version, to be called Desrem, for the treatment of suspected or laboratory confirmed severe incidences of COVID-19 in adults and children, the company said in a statement https://prn.to/2By83B9. Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug.

  • Hedge Funds Are Selling Dr. Reddy’s Laboratories Limited (RDY)
    Insider Monkey

    Hedge Funds Are Selling Dr. Reddy’s Laboratories Limited (RDY)

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19
    Business Wire

    Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, hereafter referred to as "Dr. Reddy’s") announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd. (hereafter referred to as "FUJIFILM") and Global Response Aid (hereafter referred to as "GRA") for the development, manufacture and sales of Avigan® Tablets (generic name: favipiravir), a potential treatment of COVID-19.

  • Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market
    Business Wire

    Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate) approved by the U.S. Food and Drug Administration (USFDA).

  • Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
    Business Wire

    Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F

    Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2020 was filed with the United States Securities and Exchange Commission on June 15, 2020.

  • Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir
    SmarterAnalyst

    Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir

    Dr Reddy's Laboratories Ltd. (RDY) announced that it has entered into a non-exclusive licensing agreement to manufacture and sell Gilead Sciences Inc.’s (GILD) coronavirus drug candidate remdesivir.The agreement grants Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug remdesivir, a potential treatment for COVID-19, in 127 countries including India. Financial terms of the agreement weren’t disclosed.As part of the pact, Gilead will provide technology transfer for the manufacturing of the potential drug. However, Dr. Reddy’s will be in charge of ramping up manufacturing and obtaining regulatory approval for the marketing of remdesivir in respective countries.Gilead’s investigational antiviral therapy has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat Covid-19.Shares in Gilead have dropped about 5% over the past week and were trading at $73.20 as of Friday’s close.Five-star analyst Hartaj Singh at Oppenheimer last week reiterated his Buy rating on the stock with a $90 price target (23% upside potential), saying that investors are ascribing little value to Gilead's quality emerging pipeline, and that any sustained weakness into 2Q20 should be viewed as a buying opportunity.Singh noted that although the stock has this year outperformed the broader market and its peer-group indices, the trend has reversed over the past month. He attributes three reasons for this: a rotation from biotech into other sectors, concerns around monetizing remdesivir's potential in COVID-19 and a tricky 2Q20 earnings report coming up in late July.The analyst added that Gilead’s $1 billion investment in remdesivir manufacturing, R&D and sales and marketing efforts are potentially not reflected in 2Q/3Q20 consensus earnings estimates, which could potentially lead to earnings misses.So what does the Street consensus say? TipRanks data shows that the majority of 14 analysts have a Hold rating on the stock, while the rest is divided between 10 Buys and 4 Sells, adding up to a Hold consensus. The $79.95 average price target  is less optimistic than Singh’s as it indicates 9% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: Israel Is Said To Be In Talks To Buy Moderna’s Covid-19 Vaccine Candidate 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed AstraZeneca Inks Europe Deal For 400M Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Nordstrom Delays Annual 11-K SEC Filing, Reopens 90% Of Stores * Google To Pay Publishers In Germany, Australia, Brazil For Content * Microsoft Acquires CyberX to Boost Azure’s IoT Security * Slack Seeks To Replace E-mail With Launch Of Virtual Business Platform

  • Reuters

    Indian stocks slip over concerns of rising coronavirus infections

    Indian shares slipped on Monday as a rise in domestic coronavirus cases and worries over a second wave of infections in China sapped investors' appetite for riskier assets. As of Monday, COVID-19 cases in India had surged well past 332,400 and deaths were over 9,500. India is the fourth-worst affected country in the world.

  • Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir
    Business Wire

    Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

  • Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market
    Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

  • Top Pharmaceutical Stocks for Q3 2020
    Investopedia

    Top Pharmaceutical Stocks for Q3 2020

    These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

  • Dr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt
    Business Wire

    Dr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt

    Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has completed the acquisition of select divisions of Wockhardt Limited’s ("Wockhardt") branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.

  • Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
    Zacks

    Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat

    Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

  • ACCESSWIRE

    Dr. Reddy's Laboratories Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Dr. Reddy's Laboratories Ltd. (NYSE:RDY) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on May 20, 2020 at 5:15 ...

  • Dr. Reddy’s Q4 & FY20 Financial Results
    Business Wire

    Dr. Reddy’s Q4 & FY20 Financial Results

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2020 under International Financial Reporting Standards (IFRS).

  • Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020
    Business Wire

    Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020

    Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the fourth quarter and full year ended March 31, 2020 on Wednesday, May 20, 2020 after the Board Meeting.

  • Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.
    Business Wire

    Dr. Reddy's Laboratories Received Approval for Their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced approval of ELYXYB (celecoxib oral solution 25 mg/mL) by the U.S. Food and Drug Administration (USFDA). ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. ELYXYB is the latest product emerging from Dr. Reddy’s portfolio of successful acute migraine treatments. The company is working to commercialize this product through partners.

  • Dr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market
    Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).

  • Dr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market
    Business Wire

    Dr. Reddy's Laboratories Announces the Launch of Fenofibrate Tablets USP, in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® (fenofibrate) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

  • Why an analyst bullish on Gilead says antiviral drug ‘won’t solve’ COVID-19
    MarketWatch

    Why an analyst bullish on Gilead says antiviral drug ‘won’t solve’ COVID-19

    Stat News, an award-winning publication for medical news, reported that a Chicago hospital treating severe COVID-19 patients with the antiviral medicine remdesivir is seeing rapid recoveries in fever and respiratory symptoms. Is the end of the coronavirus crisis simply a matter of Gilead wrapping up the trial, submitting the proper paperwork and scaling up manufacturing? Unlike the Chicago study, the China trial tested patients given a placebo.

  • Dr. Reddy's Laboratories Announces the Launch of an Authorized Generic Version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. Market
    Business Wire

    Dr. Reddy's Laboratories Announces the Launch of an Authorized Generic Version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System.

  • Dr. Reddy's Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market
    Business Wire

    Dr. Reddy's Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market

    Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo® (amphetamine sulfate) Tablets approved by the U.S. Food and Drug Administration (USFDA). Amphetamine Sulfate Tablets, USP is a Schedule II drug.

  • Amarin Shares Recover Somewhat After US Patent Setback
    GuruFocus.com

    Amarin Shares Recover Somewhat After US Patent Setback

    Ruling on heart drug doesn't affect potential in large international market Continue reading...

  • GuruFocus.com

    Covid-19 Could Benefit Generic Drug Companies

    Pricing is increasing for makers of copycat medicines Continue reading...

  • Dr. Reddy's Laboratories Issues Voluntary Nationwide Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening
    Business Wire

    Dr. Reddy's Laboratories Issues Voluntary Nationwide Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening

    Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as "Dr. Reddy’s") announced today that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level. The product is being recalled due to product complaints received due to ampules breaking and shattering, upon opening, during compounding.